8-K: ArriVent's Firmonertinib Trial Misses Primary Endpoint

ArriVent BioPharma announced its Phase 3 FURVENT trial for firmonertinib in NSCLC did not meet its primary endpoint of progression-free survival.

Summary

• ArriVent BioPharma's Phase 3 FURVENT trial for firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR).
• While the primary endpoint was missed, clinical benefit was observed in secondary endpoints, including PFS by investigator assessment and confirmed objective response rate (ORR) by BICR.
• A trend towards improved overall survival (OS) was also noted, though the data is not yet mature.
• The safety profile of firmonertinib was consistent with previous studies, with no new safety signals identified.
• Treatment-emergent adverse events (TEAE) Grade 3 occurred in 52% of patients on firmonertinib 240mg, 53% on 160mg, and 55% in the control arm.
• Treatment-related adverse events (TRAE) Grade 3 were 26% for firmonertinib 240mg, 22% for 160mg, and 40% for the control arm.
• The company is evaluating the full dataset to determine the future development path for firmonertinib.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the primary endpoint miss in a pivotal Phase 3 trial, significantly impacting the outlook for firmonertinib.

Positives

• Clinical benefit observed in secondary endpoints such as PFS by investigator assessment and confirmed objective response rate (ORR) by BICR.
• A trend towards improvement in overall survival (OS) was observed, although data is not yet mature.
• The safety profile of firmonertinib was consistent with previous clinical studies, with no new safety signals identified.
• Treatment-related adverse events (TRAE) Grade 3 were lower in firmonertinib arms (26% and 22%) compared to the control arm (40%).

Negatives

• The Phase 3 FURVENT trial did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR).
• Median PFS by BICR was 11.0 months for firmonertinib 240mg and 8.4 months for 160mg, compared to 9.5 months for the control arm.
• The HR for PFS (240mg vs. control) was 0.75 (95% CI: 0.55, 1.02), indicating a non-statistically significant trend towards improvement.
• The HR for PFS (160mg vs. control) was 0.91 (95% CI: 0.67, 1.25), indicating no improvement over control.
• The CEO expressed disappointment, stating the trial did not show a meaningful improvement in PFS over chemotherapy by BICR.

Risks

• The primary endpoint miss in the Phase 3 FURVENT trial could significantly impact the future development and commercialization of firmonertinib.
• The company is evaluating the full dataset to determine the most appropriate development path for firmonertinib, indicating uncertainty.
• The filing references the company's Form 10-K for the fiscal year ended December 31, 2025, filed on March 5, 2026, which contains detailed risk factors that may be relevant.
• The unmet medical need for effective treatments for EGFR exon 20 insertion-mutant NSCLC remains high, and the failure to meet the primary endpoint exacerbates this.

Future Outlook

ArriVent is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib. The company has not provided specific guidance on future trials or regulatory submissions for this indication.

Management Comments

• "These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options," said Bing Yao, Ph.D., Chairman, Chief Executive Officer of ArriVent.
• "While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study."
• "We are deeply grateful to the patients, investigators and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib."

Industry Context

StockSavvy.ai notes that the failure to meet the primary endpoint in a Phase 3 trial for a targeted therapy in NSCLC is a significant setback, especially for a rare mutation like EGFR exon 20 insertion, where treatment options are limited. This highlights the challenges in developing effective therapies for uncommon mutations and the critical importance of robust clinical trial design and execution.

Stakeholder Impact

• Shareholders may experience negative sentiment and a potential decrease in stock price due to the trial's failure to meet its primary endpoint.
• Patients with EGFR exon 20 insertion mutant NSCLC face continued unmet medical needs, as firmonertinib's efficacy in this specific indication is now in question.
• Clinical teams and investigators involved in the trial may face disappointment and need to reassess future research directions.
• Partners, such as Allist, may need to re-evaluate their collaboration strategy based on these results.

Next Steps

• ArriVent is evaluating the full FURVENT dataset.
• ArriVent will determine the most appropriate development path for firmonertinib.

Key Dates

Recommendation

The failure of the pivotal Phase 3 FURVENT trial to meet its primary endpoint of progression-free survival is a significant negative event. While secondary endpoints showed some promise and the safety profile was acceptable, the lack of statistically significant improvement in PFS over chemotherapy in a first-line setting for a targeted therapy is a major setback. This casts considerable doubt on the future development and commercial viability of firmonertinib for this indication, warranting a sell recommendation.

Keywords

firmonertinib, NSCLC, EGFR exon 20 insertion, Phase 3 trial, FURVENT, progression-free survival, non-small cell lung cancer, oncology